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Conﬂicts	  of	  Interest	  
	  
•  I	  do	  not	  accept	  $$$	  as	  salary	  from	  anyone	  
other	  than	  my	  current	  employer,	  CSHL.	  
	  
•  	  I	  also	  work	  with	  the	  nonproﬁt	  Utah	  
FoundaHon	  for	  Biomedical	  Research	  (UFBR)	  
and	  the	  InsHtute	  for	  Genomic	  Medicine	  (IGM).	  
	  
•  Any	  revenue	  that	  I	  earn	  from	  providing	  
medical	  consultaHon	  to	  	  people	  is	  donated	  to	  
UFBR	  and	  IGM	  for	  the	  geneHcs	  research.	  
“PrevenHon”	  has	  been	  and	  will	  
conHnue	  to	  be	  the	  best	  way	  to	  
improve	  health.	  
	  
BePer	  sanitaHon	  =	  reduce	  infecHous	  disease	  
	  
Iodine	  supplementaHon	  =	  eliminate	  creHnism	  
	  
Folate	  during	  pregnancy	  =	  reduce	  neural	  tube	  defects	  
	  
PAP	  smears	  =	  detect	  pre-­‐cancerous	  lesions	  
	  
Reduce	  cigarePe	  smoking	  =	  decrease	  cancer	  
	  
From	  Base	  Pair	  to	  Body	  Plan:	  
Celebra:ng	  60	  years	  of	  DNA	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Organizers:	  
Alex	  Gann,	  Cold	  Spring	  Harbor	  Laboratory	  
Robert	  MarHenssen,	  Cold	  Spring	  Harbor	  Laboratory/HHMI	  
“We	  don’t	  have	  to	  look	  for	  a	  model	  
organism	  anymore,	  because	  we	  are	  
the	  model	  organisms.”	  
	  
–	  Sydney	  Brenner,	  Nobel	  Laureate,	  
quote	  in	  2008	  
Complexity	  
•  There	  are	  ~25-­‐100	  TRILLION	  cells	  in	  each	  
human	  body,	  with	  ~6	  billion	  nucleoHdes	  per	  
cell.	  
•  There	  is	  extensive	  modiﬁcaHon	  of	  DNA,	  RNA	  
and	  proteins	  both	  spaHally	  and	  temporally.	  
•  There	  are	  higher	  level	  mechanisms	  of	  somaHc	  
mosaicism,	  heterosis,	  and	  likely	  ancestral	  
inheritance.	  
Source:	  hEp://www.thenakedscien:sts.com/HTML/features/ar:cle/jamilcolumn1.htm/	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Abstract
Most human pre-mRNAs are spliced into linear molecules that retain the exon order defined by the genomic sequence. By
deep sequencing of RNA from a variety of normal and malignant human cells, we found RNA transcripts from many human
genes in which the exons were arranged in a non-canonical order. Statistical estimates and biochemical assays provided
strong evidence that a substantial fraction of the spliced transcripts from hundreds of genes are circular RNAs. Our results
suggest that a non-canonical mode of RNA splicing, resulting in a circular RNA isoform, is a general feature of the gene
expression program in human cells.
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Introduction
Deep sequencing of RNA from biological samples, ‘‘RNA-Seq’’,
is a powerful tool for discovering and cataloguing novel alterations
in the expression, sequence, and structure of transcriptomes. In the
present study, we used RNA-Seq in a deliberate search for
transcripts that could not be accounted for by conventional
splicing of primary transcripts from an unrearranged human
genome. Although our initial goal was to discover cancer-specific
chromosomal rearrangements by identifying the resulting fused or
rearranged transcripts, we also investigated the possibility that the
exon order specified by the genome sequence might be rearranged
during RNA processing. We were surprised to find numerous
examples of transcripts in which the exon order was a circular
permutation of the order encoded in the genome. We hypothe-
sized that these anomalous transcripts might the result of
intramolecular but non-canonical splicing events that joined a
splice donor to an upstream (i.e. toward the 59 end of the
transcript) splice acceptor to produce a circular RNA molecule.
Indeed, for many genes, in both cancer and normal human cells,
we found RNAs with circularly permuted exon orders at levels
comparable to those of the canonical, linear mRNA.
The first observation suggesting that eukaryotic RNAs can exist
in circular form was made more than 30 years ago by electron
microscopy [1]. 10 years later, human cytoplasmic RNA was
reported to contain very low levels of transcripts of the DCC gene
with exons spliced in non-canonical order (i.e. shuffled relative to
the reference genome). These scrambled transcripts were estimat-
ed to comprise less than one one-thousandth of DCC transcripts,
and the phenomenon was dubbed exon-scrambling [2]. Since that
time, a handful of expressed mammalian genes have been shown
to express circular RNA isoforms at low levels [3,4]. Such
examples include very low levels of human RNA transcripts with
scrambled exons observed in several human genes, including MLL
and ETS-1 [13,14].
The best-characterized circular transcripts are in rodents. The
mouse SRY gene, the sex-determining gene in males, consists of a
single exon. During development, the RNA exists as a linear
transcript that is translated into protein. In the adult testes, the
RNA exists primarily as a circular product that is predominantly
localized to the cytoplasm and is apparently not translated [5,6].
Studies have demonstrated that inverted repeats in the genomic
sequence flanking the SRY exon direct transcript circularization
[5,7,8]. The sodium transporter NCX1 and the rat cytochrome
P450 2C24 gene are two other well-studied examples of mouse
transcripts with circular isoforms that are expressed at relatively
low levels [9–11]. The circular isoform of the NCX1 gene is
thought to encode a protein, although this possibility has not been
conclusively demonstrated. Examples of exon scrambling have
also been found in Drosophila [12].
All examples of circular transcripts reported to date in humans
have been found to be expressed at low levels compared to the
dominant canonical linear isoform, requiring sensitive nested PCR
experiments for detection; these examples were discovered
inadvertently or in an effort to characterize the structure of
oncogenes. Circular RNAs have also been reported to be rare
isoforms of the human Cytochrome P-450 2C18, and dystrophin
transcripts [11,15]. Most recently, a circular isoform of the non-
coding RNA ANRIL was found to be expressed at very low levels;
its expression was correlated with INK4/ARF expression, and
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Ogden	  Syndrome	  –	  in	  2011	  	  
We	  found	  the	  SAME	  mutaHon	  in	  two	  unrelated	  families,	  with	  a	  very	  similar	  
phenotype	  in	  both	  families,	  helping	  prove	  that	  this	  genotype	  contributes	  to	  the	  
phenotype	  observed.	  
The	  muta:on	  disrupts	  the	  N-­‐terminal	  
acetyla:on	  machinery	  (NatA)	  in	  
human	  cells.	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  Thomas	  Arnesen	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Could	  be	  X-­‐linked,	  	  Autosomal	  Recessive,	  mulH-­‐allelic	  or	  polygenic	  threshold	  eﬀect?	  
New	  Syndrome	  with	  Dysmorphology,	  Mental	  	  
RetardaHon,	  “AuHsm”,	  “ADHD”	  
1.5	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3.5	  years	  old 	   	   	   	  7	  years	  old 	   	  	  
3	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  years	  old 	   	   	   	  	  	  9	  years	  old 	  	  
Workup	  Ongoing	  for	  past	  10	  years	  
•  Numerous	  geneHc	  tests	  negaHve,	  including	  negaHve	  for	  
Fragile	  X	  and	  many	  candidate	  genes.	  
•  No	  obvious	  pathogenic	  CNVs	  –	  several	  microarrays	  
without	  any	  deﬁniHve	  result.	  
•  Sequenced	  whole	  genomes	  of	  Mother,	  Father	  and	  Two	  
Boys,	  using	  Complete	  Genomics,	  version	  2.0	  CG	  pipeline.	  
•  But	  VERY	  diﬃcult	  to	  prove	  in	  this	  instance	  that	  any	  
mutaHon	  (or	  mutaHons)	  are	  deﬁnitely	  contribuHng	  to	  
the	  illness.	  
Worldwide	  Database?	  
•  We	  need	  at	  least	  ONE	  Million	  humans	  with	  
detailed	  phenotype,	  genomic,	  and	  other	  data	  
followed	  longitudinally,	  and	  all	  available	  for	  
analysis	  to	  anyone	  online.	  
	  
•  A	  “Medical	  Donor	  InformaHon	  Network”,	  in	  
the	  words	  of	  Maynard	  Olson.	  
But	  how	  do	  ever	  achieve	  this?	  
Clinical	  Validity	  with	  Worldwide	  
Human	  GeneHc	  VariaHon	  “database”?	  
Pa:entsLikeMe	  
100,000	  Bri:sh	  Genomes	  
Networking	  of	  Science	  Model	  
	  
hEp://lyonlab.cshl.edu/publica:ons.html	  
The	  dreaded	  “Reviewer	  #3”	  
The	  dreaded	  “Reviewer	  #3”	  
•  “The	  authors	  should	  stop	  and	  take	  a	  breath.	  	  
Topol’s	  book	  (The	  CreaHve	  DestrucHon	  of	  
Medicine)	  is	  a	  popularizaHon	  of	  the	  “ﬂying	  
cars”	  variety.”	  
Scenic	  drive:	  In	  this	  undated	  photo,	  Dr.	  Paul	  Moller	  stands	  with	  two	  prototypes	  of	  his	  
SkyCar	  and	  his	  company's	  ﬂying	  saucer,	  the	  Neuera,	  which	  he	  helped	  develop	  and	  
himself	  piloted	  in	  the	  1970s	  
hPp://www.dailymail.co.uk/news/arHcle-­‐2268402/Flying-­‐car-­‐developer-­‐says-­‐hes-­‐80-­‐
million-­‐closer-­‐making-­‐sci-­‐ﬁ-­‐dream-­‐reality.html#ixzz2Ld7gJqiT	  	  
	  
	  
It	  takes	  a	  LONG	  Hme	  and	  Persistence	  
to	  introduce	  new	  technologies	  and	  
change	  the	  Status	  Quo	  
From	  Prize	  Fight:	  The	  Race	  and	  Rivalry	  to	  be	  First	  
in	  Science,	  by	  Morton	  Meyers,	  M.D.,	  2012	  
First	  Human	  Image	  July	  3,	  1977,	  showing	  
heart,	  lungs,	  vertebra,	  musculature.	  
MRI	  ~1977	  
Present	  Day	  2013,	  ~35	  years	  later	  
IndustrializaHon	  of	  Sequencing	  
to	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“If you sequence people’s exomes you’re going to find stuff,” said Gholson Lyon, 
a physician and researcher previously at the University of Utah, now at Cold 
Spring Harbor Laboratory.
As part of his research, Dr. Lyon worked with a family in Ogden, Utah. Over 
two generations, four boys had died from an unknown disease with a distinct 
combination of symptoms—an aged appearance, facial abnormalities, and devel-
opmental delay. Dr. Lyon sought to identify the genetic cause of this disease, and 
collected blood samples from 12 family members who had signed consent forms. 
"e family members understood these forms to mean that they would have access 
to their results.
Dr. Lyon conducted exon capture and sequencing of the X chromosome—a 
process that analyzes specific regions of the X chromosome and is a less expensive 
alternative to whole genome sequencing—to analyze the blood samples. Dr. 
Lyon and his colleagues identified a genetic mutation, and named the disease 
Ogden Syndrome after the family’s hometown.
After Dr. Lyon and his team identified the genetic basis of Ogden Syndrome, 
one of the family members contacted him. "is young mother of one daughter 
had submitted a blood sample for Dr. Lyon’s research. She had not been preg-
nant at the time, but was now four months pregnant with her second child. 
She knew that she was carrying a boy and wanted to know if she was a carrier 
of the mutation. She wanted to be able to mentally and emotionally prepare 
herself and her family.
By reexamining his research data, Dr. Lyon was able to see that the expectant 
mother was a carrier of Ogden Syndrome. "is meant that her son had a 50 
percent chance of being born with the disease. Dr. Lyon could not, however, 
legally share this important information with the family because he had conducted 
the original sequencing in a research laboratory that had not satisfied federally 
mandated standards designed to ensure the accuracy of clinical genetic results.
Instead, Dr. Lyon worked to have the mutation validated at a laboratory that 
satisfied those federal standards; this involved overcoming substantial bureau-
cratic hurdles and other obstacles that held up the process. During this time, 
Policy and Governance
INTRODUCTION
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the baby boy was born and died of Ogden Syndrome at four months of age. 
While knowing the results would not have changed the outcome, Dr. Lyon feels 
he should have been able to do more for the family.
Dr. Lyon has become an outspoken advocate for conducting whole genome 
sequencing in laboratories that satisfy the federal standards so that researchers 
can return results to participants, if appropriate. Dr. Lyon wants clear guid-
ance for laboratories conducting genetic research and clear language in consent 
forms that clarifies the results that participants should expect to have returned 
from the researchers.
Realizing the promise of whole genome sequencing requires widespread 
public participation and individual willingness to share genomic data and 
relevant medical information. This requires public trust that any whole 
genome sequence data shared by individuals with researchers and clinicians 
will be adequately protected. Individuals must trust that their whole genome 
sequence data will not be either intentionally or inadvertently disclosed or 
misused. Current U.S. governance and oversight of genetic and genomic 
data, however, do not fully protect individuals from the risks associated with 
sharing their whole genome sequence data and information. 
The Genetic I formatio  N ndiscrimination Act of 2008 (GINA) is the 
leading federal protection of genetic information, but it offers only prohibi-
tion of genetic discrimination in health insurance and employment. GINA 
does not regulate access, security, and disclosure of genetic or whole genome 
sequence information across all potential users, nor does it protect against 
discrimination in other contexts. U.S. state laws on genetic information 
vary greatly in their protections of individuals, and they also fail to provide 
uniform privacy protections. In an era in which whole genome sequence data 
are increasingly stored and shared using biorepositories and databases, there 
is little to no systematic oversight of these systems. 
Ethical Principles
Laws and regulations cannot do all of the work necessary to provide sufficient 
privacy protections for whole genome sequence data. Individuals who obtain 
PRIVACY and PROGRESS in Whole Genome Sequencing
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systems and infrastructure to facilitate health information exchange so that 
data can be easily aggregated and studied.213 Integrating whole genome 
sequence data into health records within the learning health system model 
can provide researchers with more data to perform genome-wide analyses, 
which in turn can advance clinical care. Several Institute of Medicine (IOM) 
working groups have supported these goals, outlining the desirability of 
establishing a universal health information technology system and learning 
environment that engages health care providers and patients. The IOM 
reports recommend that such a system include both genomic and clinical 
information, increased interoperability of medical records systems, and 
reduced barriers to data sharing.214 The President’s Council of Advisors 
on Science and Technology identified the lack of sharing electronic health 
records—with patients, with a patient’s health care providers at other 
organizations, with public health agencies, and with researchers—as a barrier 
to improved health care.215
Recommendation 4.1
Funders of whole genome sequencing research, relevant clinical entities, 
and the commercial sector should facilitate explicit exchange of information 
between genomic researchers and clinicians, while maintaining robust data 
protection safeguards, so that whole genome sequence and health data can be 
shared to advance genomic medicine.
Performing all whole genome sequencing in CLIA-approved laboratories 
would remove one of the barriers to data sharing. It would help ensure that 
whole genome sequencing generates high-quality data that clinicians and 
researchers can use to draw clinically relevant conclusions. It would also 
ensure that individuals who obtain their whole genome sequence data could 
share them more confidently in patient-driven research initiatives, producing 
more meaningful data. !at said, current sequencing technologies and those 
in development are diverse and evolving, and standardization is a substantial 
challenge. Ongoing efforts, such as those by the Standardization of Clinical 
Testing working group are critical to achieving standards for ensuring the 
reliability of whole genome sequencing results, and facilitating the exchange 
and use of these data.216
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Introduction 
 
We are entering a fascinating and uncertain period of medical history, as today’s DNA sequencing 
technology has the potential to help each of us direct our care and predict our future based on knowledge of 
our own individual inherited and acquired genetics.  However, from a global and local economic 
perspective, these are lean years, and this adds a significant degree of uncertainty to the immediate future 
of this enterprise. It is therefore incumbent upon us as a community to show that personalized genomic 
medicine will not just be a luxury or a burdensome cost center, but that it truly has the potential to save 
both lives and health care expenses via data-driven management, early disease detection/screening and 
more efficacious pharmaceutical delivery.  To do this, we need to determine how to move forward towards 
expanded clinical use of this technology in a manner both rapid and economical, while ensuring the 
integrity of the process and the safety and well-being of patients and research participants.  Here, we 
discuss some of the ethical, regulatory and practical considerations that are emerging in the field of 
genomic medicine.  We also propose that many of the cost and safety issues we are facing can be mitigated 
through expanded reliance on existing clinical regulatory frameworks and the implementation of work-
sharing strategies designed to leverage the strengths of our genomics centers and clinical interpretive 
teams. 
 
Paving the Way for the Broad Implementation of Clinical Genomic Medicine 
A report published in 2011 by the National Research Council for the National Academy of Sciences elegantly 
described the major split between the clinical and research worlds. The report went on to offer suggestions 
for how to help merge these two worlds, including articulating the need for a “Knowledge Network” and 
“New Taxonomy”, with the recommendation that small pilot studies along such lines should be conducted 
[1]. However, the report did not address a critical issue related to genetic testing in America, namely the 
rules governing such testing.  
 
The United States federal government mandates that any laboratory performing tests on human specimens 
“for the purpose of providing information for the diagnosis, prevention, or treatment of any disease” must 
satisfy the conditions set forth in the Clinical Laboratory Improvement Amendments (CLIA) of 1988 [2, 
3].  Research laboratories performing investigative analyses of human samples that are not meant to 
provide clinically actionable results are currently considered exempt, and it is a fact that most research 
laboratories do not have sufficient standards in place to qualify them for CLIA approval [4, 5].  At the time 
CLIA was enacted, the separation of the clinical and research worlds seemed a fairly straightforward 
proposition.  But today, the issues we face from a regulatory and ethical standpoint around genomics stem 
from the simple question: what do we do when it becomes difficult to draw a clear line of distinction 
between these two types of laboratory practices, particularly when researchers are working directly with 
CLIA	  and	  GeneHcs	  !
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Table 1. Processes involved in a CLIA-certified genetic test. 
Preanalytic System: 
1) test request and specimen collection criteria 
2) specimen submission, handling and referral procedures  
3) preanalytic systems assessment 
Analytic System: 
1) a detailed step-by-step procedure manual 
2) test systems, equipment, instruments, reagents, materials and supplies 
3) establishment and verification of performance specifications  
4) maintenance and function checks 
5) calibration and calibration verification procedures 
6) control procedures, test records, and corrective actions 
7) analytic systems assessment 
Post-Analytic System: 
1) test report, including (among other things): 
a) interpretation 
b) reference ranges and normal values 
2) Post-analytic systems assessment 
 
 
 
This issue is beginning to get the attention of the agencies responsible for overseeing clinical laboratories, 
now that a large number of clinical laboratories have begun developing a variety of tests on NGS 
instruments.  The College of American Pathologists (CAP) has recently released a new checklist for 
molecular pathology laboratories that includes both general laboratory and test development guidelines 
covering NGS wet lab practices, bioinformatics processing and data storage and transfer practices.  
Additionally, the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) 
has issued detailed guidelines for the development and validation of NGS cancer genomics assays [30].  
New York is one of two CLIA-exempt states as a result of its own state licensure regulations being deemed 
“equal to, or more stringent than” CLIA by CMS per CLIA subpart E, thus clinical laboratories in New York 
receive their CLIA license through the state following successful state certification.  The CLEP NGS 
oncology guidelines are quite thorough, including requirements for quality scores, control procedures, 
acceptable numbers of specimens for validation studies and guidelines for establishing read depth, 
accuracy, sensitivity, etc., focusing on actual performance rather than the details of bioinformatics 
pipelines.  Overall, the regulatory framework for NGS on the pure clinical side is coming together, with 
certain aspects such as reporting criteria hopefully being sorted out in the near future. 
 
However, if a clinical NGS test is defined by both the sequencing and downstream informatics, and the 
informatics possibilities for a standard sequence are essentially limitless, how could CLIA supervision be 
applied to combined research and clinical genomics operations without placing an extreme regulatory 
burden on the sequencing laboratory?  Would every analysis type need to be certified, or would a time-
consuming standardized analysis be required even if it were not needed for each particular operation?   
 
The Distributive Model: An Analytical-Interpretive Split Across Genomics  
Any ideal solution would allow sequencing centers to focus on their strengths and to leverage their 
economies of scale, without requiring them to devote their time to unnecessary informatics and 
interpretation.  How can that be achieved in keeping with the spirit of proper CLIA oversight?  As a 
solution, we would propose an analytic-interpretive split (or a so-called “distributive model”) across both 
clinical and research genomics.  This split model simply means that one laboratory performs analytics and 
then a second laboratory performs the interpretation and reporting.  Thus, together, the two laboratories 
perform all the functions that make up a laboratory test.  This should be a straightforward arrangement, 
but while some precedent and guidance policies exist, the regulatory structure that would govern such a 
system is still evolving, as we will discuss. 
I	  have	  ordered	  and	  obtained	  whole	  genome	  sequencing	  from	  the	  CLIA-­‐cerHﬁed	  WGS	  
lab	  at	  Illumina.	  It	  ALREADY	  exists.	  
Will	  results	  from	  my	  blood	  tests	  be	  forwarded	  to	  me?	  
	  
It	  will	  not	  be	  possible	  to	  give	  par:cipants	  results	  of	  the	  blood	  tests.	  Due	  to	  
regulaHons	  under	  the	  Clinical	  Laboratory	  Improvement	  Amendments	  (CLIA),	  we	  
are	  legally	  unable	  to	  return	  research	  results	  to	  parHcipants.	  Results	  from	  the	  
blood	  tests	  will	  not	  be	  placed	  in	  parHcipants'	  electronic	  health	  record.	  
ParHcipants	  should	  discuss	  any	  health	  concerns	  with	  their	  doctor	  or	  other	  health	  
care	  provider,	  who	  can	  arrange	  any	  necessary	  and	  appropriate	  tests.	  
	  
	   	   	   	   	   	   	  	  hPp://www.research.va.gov/mvp/veterans.cfm	  	  
	   	   	   	   	   	   	   	  accessed	  March	  6,	  2013	  
	  
	  
	  “A	  partnership	  is	  an	  arrangement	  where	  parHes	  agree	  to	  
cooperate	  to	  advance	  their	  mutual	  interests.”-­‐	  Wikipedia	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Dealing with the unexpected: consumer
responses to direct-access BRCA
mutation testing
Uta Francke1,2, Cheri Dijamco1, Amy K. Kiefer1, Nicholas Eriksson1,
Bianca MoiseV1, Joyce Y. Tung1, and Joanna L. Mountain1
1 23andMe, Inc., Mountain View, CA, USA
2 Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA
ABSTRACT
Background. Inherited BRCA gene mutations convey a high risk for breast and
ovarian cancer, but current guidelines limit BRCAmutation testing to women with
early-onset cancer and relatives of mutation-positive cases. Benefits and risks of
providing this information directly to consumers are unknown.
Methods. To assess and quantify emotional and behavioral reactions of consumers to
their 23andMe Personal Genome Service R  report of three BRCAmutations that are
common in Ashkenazi Jews, we invited all 136 BRCA1 and BRCA2mutation-positive
individuals in the 23andMe customer database who had chosen to view their BRCA
reports to participate in this IRB-approved study. We also invited 160 mutation-
negative customers who were matched for age, sex and ancestry. Semi-structured
phone interviews were completed for 32 mutation carriers, 16 women and 16 men,
and 31 non-carriers. Questions addressed personal and family history of cancer,
decision and timing of viewing the BRCA report, recollection of the result, emotional
responses, perception of personal cancer risk, information sharing, and actions taken
or planned.
Results. Eleven women and 14 men had received the unexpected result that they are
carriers of a BRCA1 185delAG or 5382insC, or BRCA2 6174delT mutation. None of
them reported extreme anxiety and four experiencedmoderate anxiety that was tran-
sitory. Remarkably, five women and sixmen described their response as neutral. Most
carrier women sought medical advice and four underwent risk-reducing procedures
after confirmatory mutation testing. Male carriers realized that their test results im-
plied genetic risk for female relatives, and several of them felt considerably burdened
by this fact. Sharing mutation information with family members led to screening
of at least 30 relatives and identification of 13 additional carriers. Non-carriers did
not report inappropriate actions, such as foregoing cancer screening. All but one
of the 32 mutation-positive participants appreciated learning their BRCAmutation
status.
Conclusions. Direct access to BRCA mutation tests, considered a model for
high-risk actionable genetic tests of proven clinical utility, provided clear
benefits to participants. The unexpected information demonstrated a cascade
eVect as relatives of newly identified carriers also sought testing and more
mutation carriers were identified. Given the absence of evidence for serious
emotional distress or inappropriate actions in this subset of mutation-positive
How to cite this article Francke U et al. (2013), Dealing with the unexpected: consumer responses to direct-access BRCAmutation
testing. PeerJ 1:e8; DOI 10.7717/peerj.8
204	  BRCA1	  (185delAG	  or	  5382i sC)	  or	  BRCA2	  6174delT	  
mutaHon	  carriers	  (130	  males	   nd	  74	  femal s)	  in	  the	  23andMe	  
database	  of	  114,627	  customers	  who	  were	  at	  least	  18	  years	  of	  
age	  and	  had	  consented	  to	  parHcipate	  in	  research.	  	  
	  
Clinical	  Validity	  with	  “Worldwide	  Human	  
Gene:c	  Varia:on	  Database”	  and/or	  
“Medical	  Donor	  Informa:on	  Network”?	  
Pa:entsLikeMe	  
100,000	  Bri:sh	  Genomes	  
Our	  Mission	  
•  Implement	  an	  infrastructure	  for	  clinical	  
genomic	  sequencing	  and	  interpretaHon.	  
•  Build	  public	  trust	  in	  genomic	  medicine.	  
•  Urge	  insurance	  companies	  to	  reimburse	  
genome	  sequencing	  in	  clinical	  setngs.	  
hPp://www.gmedicine.org	  hPp://www.utahresearch.org/	  
Figure 4.	

	

Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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•  @Katy_Read:	  Like	  many	  writers,	  I	  have	  rituals.	  
Before	  wriHng,	  I	  pour	  some	  coﬀee,	  open	  the	  
window	  by	  my	  desk,	  and	  aPempt	  to	  read	  the	  
enHre	  internet.	  
